Larvol Delta - BioCryst-Pharmaceuticals-Incannounced-that-Japans-Ministry-of-Health-Labor-and-Welfare-MHLW-has-granted-marketing-approval-for-oncedaily-ORLADEYO-berotralstat-for-prophylactic-therapy-in-pediatric-patients-with-hereditary-angioedema-HAE-aged-2-to-lt12-years

Orladeyo (berotralstat) - BioCryst Pharmaceuticals

https://www.globenewswire.com/news-release/2026/08/25/3350321/29446/en/biocryst-announces-approval-of-orladeyo-for-pediatric-hae-patients-in-japan.html

Aug 25, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next